All In Biotech

Drug Trial Radar · NCT01406977

Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)

An Open-label, Intra-patient Dose-escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP).

Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jul 2011

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
Collaborators
Mereo BioPharma; Novartis
First posted
Aug 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine tolerability, PK/PD and preliminary efficacy of BPS804 in adult patients with HPP treated with multiple escalating doses of BPS804. This study will allow a comparison of several doses of the study drug within the first two weeks after administration and after a longer assessment period for the highest dose level to enable selection of dose ranges to be tested in subsequent studies in the HPP indication.

Conditions

  • Hypophosphatasia

Interventions

  • BPS804Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number (percent) of patients experiencing adverse events or serious adverse eventsTime frame: 141 days following initial investigational product administration
  2. Change from baseline in primary serological bone biomarkersTime frame: 141 days following initial investigational product administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mereo BioPharma 3 Ltd Investigative Site

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.